10 Best Selling Drugs

No 10  Xarelto
No 10 Xarelto

Xarelto, which brought home sales of 3.631 billion euros for Bayer and $2.477 billion for Johnson & Johnson in 2018, is ranked the 10th top-selling drug of the year. (1 Euro is equal to 1.12444 USD, as of April 4, 2019).

The drug is indicated to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, treat deep vein thrombosis, pulmonary embolism, reduce the risk of recurrence of deep vein thrombosis and of pulmonary embolism, and prophylaxis of deep vein thrombosis.

Xarelto received its initial approval in the European Union in September 2008, and in the U.S. in July 2011.

The patent protection for the active ingredient of Xarelto in the U.S. runs until August 28, 2024, and in the European Union between 2020 and 2025.